Tag:
Andrew Witty
Latest Headlines
Latest Headlines
GSK chief rules out AstraZeneca buyout
A buyout, he said, would be "very distracting".
GSK's Witty winning at pharma chess in post-blockbuster era
Andrew Witty has made a number of deft moves in recent years to position GlaxoSmithKline ($GSK) for growth despite numerous challenges to Big Pharma.
GSK's Witty calls for joint effort on antibiotic development
In a wide-ranging interview with The Wall Street Journal , GlaxoSmithKline ($GSK) CEO Andrew Witty highlighted the company's involvement in an industry effort to develop new treatments for tropical diseases.
GSK to invest more than £500 million in new manufacturing in U.K.
GlaxoSmithKline ( $GSK ) has decided to build a £350 million ($463 million) plant in Ulverston, U.K., but to also invest another £230 million ($304 million) at the other three sites the company was considering.
UPDATED: GSK investing in U.K. vaccine manufacturing
GlaxoSmithKline has announced that it intends to invest more than £500 million ($794 million) and create up to 1,000 jobs in vaccine and pharmaceutical manufacturing in the U.K.
After big hike in 2011, GSK CEO's pay set to jump again
GlaxoSmithKline ( $GSK ) CEO Andrew Witty ( photo ) saw a big pay hike in 2011--and he's due another increase this year, the company's compensation committee says. Last year, Witty collected a...
GSK to add hundreds to Chinese sales force, CEO says
GlaxoSmithKline ( $GSK ) is steaming ahead in China. CEO Andrew Witty ( photo ) tells Bloomberg he plans to add "a few hundred" sales folks to back up products his company is introducing there. That's on top of 700 hires in 2011. And, Witty said, he'd like to augment his Chinese operations with some M&A, too.
GSK chief: Officials delay new meds to save money
GlaxoSmithKline ( $GSK ) chief Andrew Witty is raising a ruckus in Europe.
A bright side to Europe's woes: U.S., Japan look better
Europe is making the U.S. and Asia look much sweeter to drugmakers. Price cuts, slow adoption of new medicines, and, of course, unpaid bills, have disillusioned pharma companies accustomed to
GSK moves European cash to U.K. nightly 'just in case'
GlaxoSmithKline ( $GSK ) executives like to sleep well at night, not wake up worrying about a banking crisis. So, the company transfers millions of euros every day into U.K. bank accounts to keep cash
